Skip to main content
. Author manuscript; available in PMC: 2019 Sep 16.
Published in final edited form as: Curr Pharm Des. 2017 Nov 16;23(29):4226–4246. doi: 10.2174/1381612823666170616082125

Table 7.

Inhibitors targeting MEK/ERK signaling

Inhibitor Target Types of cancer
Trametinib (GSK) [227] Allosteric MEK Melanoma, colorectal cancer, neuroblastoma, lung cancer
PD0325901[228] Allosteric MEK Colorectal cancer, solid tumor,
Selumetinib [229] Allosteric MEK Triple-negative breast cancer, melanoma, lung cancer, head and neck carcinoma
Cobimetinib [230] Allosteric MEK Melanoma,
RO5126766 [231] Allosteric MEK Solid tumor, multiple myeloma
SCH772984 [235] ATP competitive ERK KRAS-mutant lung cancer
VX11e [237] ATP competitive ERK BRAF-inhibitor progressed melanoma